Could a tropical berry boost immunotherapy for kidney cancer?
NCT ID NCT06049576
First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. The study looks at changes in gut bacteria and tumor response, aiming to see if the prebiotic helps the immune system fight cancer better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camu camu (a prebiotic fruit extract) combined with nivolumab and ipilimumab (immunotherapy drugs)
- What this could lead to
- If it works, adding camu camu could boost the immune system's ability to fight kidney cancer, potentially improving how well standard immunotherapy works.
- What could go wrong
- This is a very early phase 1 trial with only 31 people, so it is mainly checking safety and dosing. It is too soon to know if camu camu truly helps, and it may not lead to better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer